Natalie A Hawryluk from 4379 Mistral Pl, San Diego, CA 92130, age 52, Phone: 6175154558

Resumes

Director, Research And Early Development, Global Health

view source

Location:

San Diego, CA

Industry:

Pharmaceuticals

Work:

Janssen, Pharmaceutical Companies of Johnson and Johnson since Feb 2010
Senior Scientist
Johnson & Johnson - Greater San Diego Area Aug 2003 - Feb 2010
Scientist
Pfizer - Groton, CT 1994 - 1997
Assistant Scientist

Education:

Harvard University 2000 - 2003
Post-Doc, NIH, Organic Chemistry Brandeis University 1997 - 2000
PhD, Organic Chemistry University of Illinois at Urbana-Champaign 1990 - 1994
BS, Chemistry

Skills:

Medicinal Chemistry
Organic Chemistry
Drug Discovery
Organic Synthesis
Drug Design
Chemistry
Pharmaceutical Industry
Drug Development
Pharmacology
Hplc
Chromatography
Neuroscience
Cro
Nmr
Lead Change
Clinical Development
Lifesciences
Patents
Team Leadership

Interests:

Health

Languages:

Ukrainian

Us Patents

Aryl-Hydroxyethylamino-Pyrimidines And Triazines As Modulators Of Fatty Acid Amide Hydrolase
view source
US Patent:

8598202, Dec 3, 2013
Filed:

Feb 18, 2009
Appl. No.:

12/378734
Inventors:

Richard Apodaca - La Jolla CA, US
J. Guy Breitenbucher - Escondido CA, US
Alison L. Chambers - San Diego CA, US
Xiaohu Deng - San Diego CA, US
Natalie A. Hawryluk - San Diego CA, US
John M. Keith - San Diego CA, US
Neelakandha S. Mani - San Diego CA, US
Jeffrey E. Merit - Stanford CA, US
Joan M. Pierce - San Diego CA, US
Mark Seierstad - Escondido CA, US
Wei Xiao - San Diego CA, US
Assignee:

Janssen Pharmaceutica NV - Beerse
International Classification:

A01N 43/54
A61K 31/505
US Classification:

514311, 544242, 514275
Abstract:

Certain aryl-hydroxyethylamino-pyrimidine and triazine compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, energy metabolism disorders, and movement disorders (e. g. , multiple sclerosis). Methods of synthesizing such compounds are also disclosed.

Heteroaryl-Substituted Urea Modulators Of Fatty Acid Amide Hydrolase
view source
US Patent:

8598356, Dec 3, 2013
Filed:

Nov 24, 2009
Appl. No.:

13/131061
Inventors:

J. Guy Breitenbucher - Escondido CA, US
John M. Keith - San Diego CA, US
Mark S. Tichenor - San Diego CA, US
Alison L. Chambers - San Diego CA, US
William M. Jones - San Diego CA, US
Natalie A. Hawryluk - San Diego CA, US
Amy K. Timmons - Renton WA, US
Jeffrey E. Merit - Stanford CA, US
Mark J. Seierstad - Escondido CA, US
Assignee:

Janssen Pharmaceutica NV - Beerse
International Classification:

C07D 211/68
A61K 31/445
US Classification:

546194, 514318
Abstract:

Certain heteroaryl-substituted piperidinyl and piperazinyl urea compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, insulin resistance, diabetes, osteoporosis, and movement disorders (e. g. , multiple sclerosis).

Tetrahydro-Pyrimidoazepines As Modulators Of Trpv1
view source
US Patent:

20070225275, Sep 27, 2007
Filed:

Mar 21, 2007
Appl. No.:

11/726756
Inventors:

Brett Allison - Del Mar CA, US
Bryan Branstetter - Carlsbad CA, US
James Breitenbucher - Escondido CA, US
Michael Hack - San Diego CA, US
Natalie Hawryluk - San Diego CA, US
Alec Lebsack - San Diego CA, US
Kelly McClure - Ramona CA, US
Jeffrey Merit - San Diego CA, US
International Classification:

A61K 31/55
C07D 487/02
US Classification:

514215000, 540578000
Abstract:

Certain tetrahydro-pyrimidoazepine compounds are described, which are useful as TRPV1 modulators. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by TRPV1. Thus, the compounds may be-administered to treat, e.g., pain, itch, cough, asthma, or inflammatory bowel disease.

Heteroaryl-Substituted Urea Modulators Of Fatty Acid Amide Hydrolase
view source
US Patent:

20090062294, Mar 5, 2009
Filed:

May 23, 2008
Appl. No.:

12/126389
Inventors:

Richard Apodaca - San Diego CA, US
J. Guy Breitenbucher - Escondido CA, US
Natalie A. Hawryluk - San Diego CA, US
William M. Jones - San Diego CA, US
John M. Keith - San Diego CA, US
Jeffrey E. Merit - San Diego CA, US
Mark S. Tichenor - San Diego CA, US
Amy K. Timmons - Renton WA, US
International Classification:

A61K 31/501
C07D 401/00
C07D 403/00
C07D 403/14
A61P 35/00
A61P 25/00
A61P 1/04
A61P 9/00
A61P 37/00
A61P 31/12
A61P 1/00
A61K 31/445
A61K 31/496
US Classification:

51425202, 544368, 51425404, 51425403, 51425405, 544366, 544379, 51425213, 51425203, 544238, 514326, 546209, 544371, 51425211, 51425214, 544316, 544363, 51425218
Abstract:

Certain heteroaryl-substituted piperidinyl and piperazinyl urea compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, insulin resistance, diabetes, osteoporosis, and movement disorders (e.g., multiple sclerosis).

Heteroaryl-Substituted Urea Modulators Of Fatty Acid Amide Hydrolase
view source
US Patent:

20110237596, Sep 29, 2011
Filed:

Nov 24, 2009
Appl. No.:

13/131067
Inventors:

J. Guy Breitenbucher - Escondido CA, US
John M. Keith - San Diego CA, US
Mark S. Tichenor - San Diego CA, US
Alison L. Chambers - San Diego CA, US
William M. Jones - San Diego CA, US
Natalie A. Hawryluk - San Diego CA, US
Amy K. Timmons - Renton WA, US
Jeffrey E. Merit - Stanford, CA
Mark J. Seierstad - Escondido CA, US
International Classification:

A61K 31/5025
C07D 413/14
A61K 31/497
A61K 31/4709
A61P 25/24
C07D 471/04
A61K 31/4353
C07D 487/04
A61P 25/22
A61P 29/00
A61P 3/00
A61P 31/18
A61K 31/501
A61P 25/00
A61P 25/28
A61P 25/16
A61P 25/30
A61P 27/02
A61P 37/00
A61P 15/00
A61P 1/00
A61P 1/12
A61P 1/04
A61P 19/02
A61P 9/12
A61P 35/00
A61P 37/08
A61P 3/10
US Classification:

514248, 544367, 51425404, 514314, 546167, 546121, 514300, 544236, 546113, 544364, 51425304, 544238, 51425202, 544281, 51425216
Abstract:

Certain heteroaryl-substituted piperidinyl and piperazinyl urea compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, insulin resistance, diabetes, osteoporosis, and movement disorders (e.g., multiple sclerosis).

Ethylene Diamine Modulators Of Fatty Acid Hydrolase
view source
US Patent:

20120149696, Jun 14, 2012
Filed:

Aug 17, 2010
Appl. No.:

13/390984
Inventors:

Natalie A. Hawryluk - San Diego CA, US
J. Guy Breitenbucher - Escondido CA, US
William M. Jones - San Diego CA, US
Alison L. Chambers - San Diego CA, US
John M. Keith - San Diego CA, US
International Classification:

A61K 31/505
C07D 409/04
C07D 417/12
A61K 31/506
A61P 25/22
A61P 25/24
A61P 25/00
A61P 3/04
A61P 29/00
A61P 25/14
A61P 25/28
A61P 25/08
A61P 25/16
A61P 27/02
A61P 25/30
A61P 1/08
A61P 15/00
A61P 27/06
A61P 1/00
A61P 37/06
A61P 1/04
A61P 1/12
A61P 15/04
A61P 9/12
A61P 35/00
A61P 31/14
A61P 37/08
A61P 37/00
A61P 17/04
A61P 3/10
A61P 3/00
A61P 19/10
A61P 19/00
C07D 239/42
US Classification:

5142278, 544326, 514256, 544328, 544 586
Abstract:

Certain ethylene diamine compounds of Formula (I) are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, energy metabolism disorders, and movement disorders (e.g., multiple sclerosis). Methods of synthesizing such compounds are also disclosed.

Piperazinecarboxamide Derivative Useful As A Modulator Of Fatty Acid Amide Hydrolase (Faah)
view source
US Patent:

20120225097, Sep 6, 2012
Filed:

Nov 10, 2010
Appl. No.:

13/508975
Inventors:

Natalie A. Hawryluk - San Diego CA, US
International Classification:

A61K 39/00
A61K 31/496
A61P 25/22
A61P 25/24
A61P 25/20
A61P 29/00
A61P 3/04
A61P 31/18
A61P 25/00
A61P 25/28
A61P 25/08
A61P 25/16
A61P 27/02
A61P 37/00
A61P 25/30
A61P 15/00
A61P 1/00
A61P 37/06
A61P 1/12
A61P 1/04
A61P 19/02
A61P 9/12
A61P 35/00
A61P 37/08
A61P 3/10
A61P 3/00
A61P 19/10
C07D 401/12
US Classification:

4242781, 544360, 51425301
Abstract:

N-Pyridin-3-yl-4-{3-[4-(trifluoromethyl)phenoxy]benzyl}piperazine-1-carboxamide is described, which is useful as a FAAH inhibitor. N-Pyridin-3-yl-4-{3-[4-(trifluoromethyl)phenoxy]benzyl}piperazine-1-carboxamide may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, energy metabolism disorders, and movement disorders (e.g., multiple sclerosis). A method of synthesizing N-pyridin-3-yl-4-{3-[4-(trifluoromethyl)phenoxy]benzyl}piperazine-1-carboxamide is also disclosed.

Heteroaryl-Substituted Urea Modulators Of Fatty Acid Amide Hydrolase
view source
US Patent:

20130245022, Sep 19, 2013
Filed:

May 3, 2013
Appl. No.:

13/886857
Inventors:

John M. Keith - San Diego CA, US
Mark S. Tichenor - San Diego CA, US
Alison L. Chambers - San Diego CA, US
William M. Jones - San Diego CA, US
Natalie A. Hawryluk - San Diego CA, US
Amy K. Timmons - San Diego CA, US
Jeffrey E. Merit - San Diego CA, US
Assignee:

Janssen Pharmaceutica NV - New Brunswick NJ
International Classification:

C07D 498/04
C07D 231/56
C07D 413/12
C07D 487/04
C07D 295/195
US Classification:

514248, 544236, 544362, 51425304, 51425306, 544363, 544368, 51425402, 544371, 51425406, 544238, 51425202
Abstract:

Certain heteroaryl-substituted piperidinyl and piperazinyl urea compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, insulin resistance, diabetes, osteoporosis, and movement disorders (e.g., multiple sclerosis).